increases the likelihood of quitting success‖
1 starting month + 2 continuing months=3 total months
|Week 1 (titration)
||Weeks 2 through 12
Before prescribing CHANTIX, ask your patients if they have any history of
psychiatric disorders. Quitting smoking, with or without treatment, has
been known to exacerbate underlying psychiatric conditions.1-3
Set patient expectations
- Remind patients to titrate up during week1
- Encourage patients to take the full 12 weeks of CHANTIX
- Instruct patients to take CHANTIX after eating, with water
- Prepare patients for the possibility of nausea and abnormal dreams (see below for incidence and discontinuation rates)
- Consider reducing dosage for cases of intolerance
- Encourage patients to continue their quit attempt even if they slip up and smoke during treatment because some patients may successfully quit smoking later in the
course of therapy4
- Be sure to discuss with patients the safety information, including the Warnings and Precautions, in the Prescribing Information
- Explain to patients that a support program may be helpful,5 and inform them about the CHANTIX GETQUIT® Plan
In a post hoc analysis of data pooled from 2 head-to-head pivotal trials
Every week of the 12-week trial treatment phase, more smokers who received CHANTIX quit and stayed quit through week 126,7*‖
Incidence and discontinuation rates due to nausea and abnormal dreams in CHANTIX clinical trials§
Of participants who received CHANTIX 0.5 mg bid throughout the 12-week course of treatment:
- 16% reported nausea vs 10% of participants who received placebo
- 9% reported abnormal dreams vs 5% of participants who
Please scroll for Important Safety Information and Indication
IMPORTANT SAFETY INFORMATION
All patients being treated with CHANTIX should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide. These symptoms, as well as worsening of pre-existing psychiatric illness and completed suicide have been reported in some patients attempting to quit smoking while taking CHANTIX in the postmarketing experience.
These events have occurred in patients with and without pre-existing psychiatric disease. Patients with serious psychiatric illness such as schizophrenia, bipolar disorder, and major depressive disorder did not participate in the premarketing studies of CHANTIX.
Advise patients and caregivers that the patient should stop taking CHANTIX and contact a healthcare provider immediately if agitation, hostility, depressed mood, or changes in behavior or thinking that are not typical for the patient are observed, or if the patient develops suicidal ideation or suicidal behavior. In many postmarketing cases, resolution of symptoms after discontinuation of CHANTIX was reported, although in some cases the symptoms persisted; therefore, ongoing monitoring and supportive care should be provided until symptoms resolve.
CHANTIX is contraindicated in patients with a history of serious hypersensitivity or skin reactions to CHANTIX.
During clinical trials and the postmarketing experience, there have been reports of seizures in patients treated with CHANTIX, with or without a history of seizures. CHANTIX should be used cautiously in patients with a history of seizures or other factors that can lower the seizure threshold. Instruct patients to discontinue CHANTIX, and contact a healthcare provider immediately if they experience a seizure while on treatment.
There have been postmarketing reports of patients experiencing increased intoxicating effects of alcohol while taking CHANTIX, including unusual and sometimes aggressive behavior directed to oneself or to others and often accompanied by amnesia. Advise patients to reduce the amount of alcohol they consume while taking CHANTIX until they know whether CHANTIX affects their tolerance for alcohol.
Patients should be informed that there have been reports of serious skin reactions, such as Stevens Johnson Syndrome and Erythema Multiforme and of angioedema, with swelling of the face, mouth, and neck that can lead to life-threatening respiratory compromise. Patients should be instructed to discontinue CHANTIX and immediately seek medical care if they experience these symptoms or at the first sign of rash with mucosal lesions or any other signs of hypersensitivity.
In a meta-analysis of clinical trials including a trial in patients with stable cardiovascular disease, while serious cardiovascular events were infrequent overall, certain serious cardiovascular events were reported more frequently in patients treated with CHANTIX than placebo. These events occurred primarily in patients with known cardiovascular disease. Instruct patients to notify their healthcare providers of new or worsening cardiovascular symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction or stroke.
The most common adverse reactions include nausea (30%), abnormal dreams, constipation, flatulence, and vomiting. Patients should be informed that they may experience vivid, unusual, or strange dreams during treatment with CHANTIX. Patients should be advised to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know how CHANTIX may affect them.
Safety and efficacy of CHANTIX in combination with other smoking cessation drug therapies have not been studied. Dosage adjustment with CHANTIX is recommended in patients with severe renal impairment or in patients undergoing hemodialysis.
Smoking cessation, with or without treatment with CHANTIX, may alter the pharmacokinetics or pharmacodynamics of some drugs, such as theophylline, warfarin, and insulin. Dosage adjustment for these drugs may be necessary.
CHANTIX is indicated as an aid to smoking cessation treatment in adults 18 and over. Patients may benefit from behavioral modification and support during their quit attempt. Patients should be encouraged to continue to attempt to quit if they have lapses after quit day.